Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
Follow-Up Questions
Qui est le CEO de Neuronetics Inc ?
Mr. Keith Sullivan est le President de Neuronetics Inc, il a rejoint l'entreprise depuis 2020.
Quelle est la performance du prix de l'action STIM ?
Le prix actuel de STIM est de $2.77, il a decreased de 3.48% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Neuronetics Inc ?
Neuronetics Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Neuronetics Inc ?
La capitalisation boursière actuelle de Neuronetics Inc est de $183.1M
Est-ce que Neuronetics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Neuronetics Inc, y compris 2 achat fort, 6 achat, 1 maintien, 0 vente et 2 vente forte
